Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
about
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifeneEndocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?The evolution of selective estrogen receptor modulators in osteoporosis therapyThe 2.0 Å crystal structure of the ERα ligand-binding domain complexed with lasofoxifeneLasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophyLasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosisPharmacology and clinical applications of selective estrogen receptor modulators.Antiosteoporotic effects of Polycan in combination with calcium lactate-gluconate in ovariectomized rats.Lasofoxifene: Evidence of its therapeutic value in osteoporosis.Selective estrogen receptor modulators: tissue specificity and clinical utility.Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifeneEmerging and potential therapies for osteoporosis.Developments in the pharmacotherapeutic management of osteoporosis.Emerging pharmacologic therapies for osteoporosis.Polycan, a β-glucan from Aureobasidium pullulans SM-2001, mitigates ovariectomy-induced osteoporosis in rats.A new approach to menopausal therapy: the tissue selective estrogen complex.Current, new and future treatments of osteoporosis.Evolution of the tissue selective estrogen complex (TSEC).Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis.Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ERα expression and uterine wet weight in ovariectomized rats.
P2860
Q24652524-5C54F3CD-C48E-4C77-919F-9DBF4F8CA1E4Q24810287-CB681BBB-3DB0-4956-8ECF-2768B2233B97Q26827973-E06CEE84-7C91-4E7C-A42E-72CD97FCBF9FQ27644597-1B262275-B52F-4834-BFFF-8B55AC1E0C1FQ28253298-E73DC45F-1695-497D-93F8-CD14ECE87CA0Q28258418-2C2A825D-1859-40EB-A6EE-009053EBB330Q33384192-E7232795-90A9-49C7-8906-A24CF75751D3Q33962186-6773DB51-5F8F-4683-8334-F6881C4AF7DCQ33973891-A08CE9B3-A592-4572-A501-9B0C22680AABQ34134828-1020A7B3-04DD-46E3-B304-6BF7BB7811E0Q34563592-87B53CA2-600C-4632-959D-8DE47809F865Q34563947-64ABF221-FABB-48B6-B5AC-9B22B3FF4837Q34568883-ECE6C00F-328C-4FEF-AE63-6CFBD39A7C91Q36099415-52AD0648-112B-482E-8C28-A86676F3BA5CQ36548722-F5A70676-198A-4A15-8077-1AB32680B0C9Q36944034-A1C2C94A-57D9-4D4C-A15C-46FC426BB376Q37204569-E01B884C-F8E3-46A0-8AB4-E3DB87051218Q37352516-1DA8E1F1-5BC5-4F70-9023-B7653F2C5218Q37777053-235AE8FF-F8F4-4659-854B-1EBCEC909416Q38077503-2A0F7D6A-E90A-4365-881E-8F05655F76A6Q39788803-98A47440-1028-4CFE-93AC-314F6A9F4754Q42836293-075234C9-65B7-460F-B05D-D4CDC4E3B57FQ46807639-37356BBB-834D-41C1-9522-2265DE23485BQ47406325-F9DB00F0-AE23-4154-8EBD-F657734CD473
P2860
Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@ast
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@en
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@nl
type
label
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@ast
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@en
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@nl
prefLabel
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@ast
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@en
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@nl
P2093
P356
P1433
P1476
Long-term treatment of lasofox ...... uterus in ovariectomized rats.
@en
P2093
David D Thompson
George L Foley
Hollis A Simmons
Hua Zhu Ke
Victor Shen
P304
P356
10.1210/EN.2003-1481
P407
P577
2004-01-15T00:00:00Z